(Reuters) -Telehealth firm Hims & Hers Health said on Tuesday it plans to sell Eli Lilly's diabetes and weight-loss drugs on ...
Eli Lilly quickly disassociated itself from Hims & Hers after the telehealth company said it was selling the pharmaceutical ...
Eli Lilly is broadening its direct-to-consumer approach by partnering with a digital health company, Noom, which is focused ...
Eli Lilly (LLY) is taking legal action against makers of off-brand versions of its blockbuster diabetes and weight-loss drugs ...
The telehealth company Hims & Hers Health is expanding its weight-loss offerings by adding new medications to its platform.
In a statement on its website, Eli Lilly and Company (LLY) said it has no affiliation with hims & hers (HIMS). It added, “Zepbound can be ...
This integration evolves Noom’s comprehensive approach to weight management by enabling a streamlined solution for members ...
Zepbound, Mounjaro and liraglutide are part of the class of weight loss medications called GLP-1s, which have exploded in ...
Hims & Hers Health shares jumped Tuesday as the company added Eli Lilly’s weight-loss drug Zepbound and diabetes treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback